| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 7,170 | 7,070 | 6,110 | 9,070 | 7,000 |
| Sales Growth | +1.41% | +15.71% | -32.64% | +29.57% | -0.85% |
| Net Income | -20 | -280 | -630 | -1,330 | -210 |
| Net Income Growth | +92.86% | +55.56% | +52.63% | -533.34% | -105.83% |
American Shared Hospital Services (AMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
American Shared Hospital Services provides turnkey technology solutions for advanced radiosurgical and radiation therapy services. AMS is the world leader in providing Gamma Knife radiosurgery services, a non-invasive treatment for malignant and benign brain tumors, vascular malformations and trigeminal neuralgia . The Company also offers the latest IGRT and IMRT systems, as well as its proprietary Operating Room for the twenty first Century concept. Through its equity investment in Still River Systems, AMS also plans to complement these services with the Clinatron-two hundred fifty, proton beam radiation therapy system, which has not yet been approved by the FDA.
Fiscal Year End Date: 12/31